Tasigna (nilotinib)
- Region
- 🇪🇺 EU
- Active substance
- nilotinib
- Company
- Novartis Europharm Limited
- Status
- Authorised
- Therapeutic area
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- EU approval
- Mon 19 Nov 2007
- Application
- EMEA/H/C/000798
- ATC
- L01EA03
- Official record
- www.ema.europa.eu
Indication
Tasigna is indicated for the treatment of: adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase, paediatric patients with Philadelphia chromosome positive CML in chronic phase with resistance or intolerance to prior therapy including imatinib. Tasigna is indicated for the treatment of: adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase, adult patients with chronic phase and accelerated phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib. Efficacy data in patients with CML in blast crisis are not available, paediatric patients with chronic phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇺🇸 Cavhanza Approved · Cycle
- 🇪🇺 Nilotinib Accord Authorised · Accord Healthcare S.L.U.
Follow Tasigna
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.